

## Disclosures

### Personal Commercial (13)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
Amarin	Consultant Fees/Honoraria	Modest (< \$5,000)	
Amgen Inc.	Research/Research Grants ‡ OCEAN(a) OUTCOMES	None (\$0)	
Amgen Inc.	Research/Research Grants ‡ Investigator-initiated study	None (\$0)	
IONIS	Research/Research Grants ‡ CS-9 (Olezarsen)	None (\$0)	
Kaneka	Consultant Fees/Honoraria	Modest (< \$5,000)	
Mineralfys	Research/Research Grants ‡ PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT IN SUBJECTS WITH UNCONTROLLED HYPERTENSION ON A STANDARDIZED MEDICATION REGIMEN	None (\$0)	
Novartis Corporation	Research/Research Grants ‡ VICTORION PLAQUE	None (\$0)	
Novartis Corporation	Research/Research Grants ‡ VICTORION 1 PREVENT	None (\$0)	
Novartis Corporation	Research/Research Grants ‡ Institutional consulting agreement for research (funds paid to institution)	None (\$0)	
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	
Regeneron	Speaker's Bureau	Modest (< \$5,000)	
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	
The Kinetix Group	Consultant Fees/Honoraria	Modest (< \$5,000)	

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (1)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
National Lipid Association	Other - Pacific Lipid Association Board Member and President-elect	None (\$0)	

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

## **Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/11/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

## **Embargo** | Signed on 10/11/2023

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **On-Going Obligation Agreement** | Signed on 10/11/2023

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.